Home
/

Stroke

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Key takeaway:

Blood testing for stroke risk measures LDL, HDL, ApoB, Lp(a), hs-CRP, NLR, and MLR to profile atherogenic particle burden and vascular inflammatory tone that together are associated with cerebrovascular plaque formation and instability. Ideally, LDL stays under 100 mg/dL and ApoB under 80–90 mg/dL, while hs-CRP below 1 mg/L signals low inflammation. Combining these seven markers with blood pressure, glucose, kidney function, and heart rhythm sharpens cerebrovascular risk estimation.

Read more →
Table of contents

Stroke Risk and the Blood Markers Behind It

Stroke biomarkers are measurable signals in blood that reflect injury to the brain or its circulation. When a blood vessel in the brain is blocked or bleeds, brain cells and support cells release proteins, and the body’s clotting and immune systems switch on. Testing for these markers can help flag brain injury early, hint at the type of stroke, and track the extent and evolution of damage and repair. Examples include proteins from injured astrocytes and glia (GFAP, S100B), from neurons and axons (NSE, neurofilament light), and signals of clot formation and breakdown (D-dimer, fibrin degradation products) or vascular stress and inflammation (CRP, cytokines). These molecules rise and fall over hours to days, offering a timeline of the event and its aftermath. In practice, blood-based biomarkers complement imaging and examination by adding biological context: they can support rapid triage, guide decisions about clot-busting or bleeding risks, and monitor secondary injury and recovery. In short, they translate microscopic brain events into accessible, actionable information.

Interpreting ApoB, LDL, HDL, Lp(a), and hs-CRP

Stroke biomarkers show how ready arteries and blood are to form brain‑blocking clots. They reflect two engines: atherogenic lipoproteins that build plaque and inflammatory immune tone that destabilizes plaques across liver‑vessel‑immune systems.For lipids, lower is safer: LDL ideally under 100; risk rises above 130 and especially 160. ApoB (particle count) is lower‑better, often under 80–90; risk up above 100. HDL protects when higher—above 40 in men, 50 in women; 60 often favorable. Lp(a) is genetic: below 30 is common; 50 or higher adds risk. Inflammation markers: hs‑CRP under 1 low, 1–3 average, over 3 high. NLR ~1–3; higher shows stressed innate immunity. MLR ~0.2–0.3; higher links to atherosclerosis. Pregnancy raises hs‑CRP, NLR, and Lp(a); children often have lower LDL/ApoB.Low LDL, ApoB, Lp(a), hs‑CRP, NLR, and MLR signal fewer plaque‑seeding particles and a quieter immune state—lower ischemic stroke risk, typically no symptoms. Extremely low LDL/ApoB from rare genetics can accompany fat‑soluble vitamin issues. Very low leukocyte ratios with infections may reflect immunosuppression. Low HDL is different: it often signals insulin resistance and relates to higher stroke risk; thresholds are lower in men than women.Together, these tests link lipid transport, endothelial health, and innate immunity—the networks that shape brain‑artery disease over decades. Alongside blood pressure, glucose, kidney function, heart rhythm, and family history, they sharpen risk estimation and long‑term outlook.

What These Markers Say About Stroke Risk

Stroke blood testing provides a window into the health of your cardiovascular and immune systems—two key players in brain function, energy, and overall resilience. At Superpower, we measure LDL, HDL, ApoB, Lp(a), hs-CRP, NLR, and MLR to assess your risk landscape for stroke. These biomarkers help us understand how well your body manages blood flow, inflammation, and vessel stability, all of which are crucial for protecting the brain from injury.LDL (low-density lipoprotein) and ApoB (apolipoprotein B) reflect the amount and type of cholesterol-carrying particles that can contribute to plaque buildup in arteries, a major risk factor for stroke. HDL (high-density lipoprotein) helps remove cholesterol from the bloodstream, offering some protection. Lp(a), or lipoprotein(a), is a genetic variant of LDL that can further increase stroke risk by promoting clot formation and arterial damage. hs-CRP (high-sensitivity C-reactive protein) is a marker of systemic inflammation, which can destabilize blood vessels. NLR (neutrophil-to-lymphocyte ratio) and MLR (monocyte-to-lymphocyte ratio) are indicators of immune system activity and inflammation, both of which can influence stroke risk and recovery.Optimal levels of these markers suggest stable blood vessels, balanced immune responses, and efficient cholesterol transport—all essential for reducing the likelihood of stroke and supporting healthy brain function. When these markers are out of range, it may signal increased vulnerability to vascular injury or inflammation.Interpretation of these results depends on factors like age, sex, genetics, current illness, medications, and even recent infections. Laboratory methods and reference ranges can also vary, so results are best understood in context.

FAQs

It’s a blood panel that maps the biology driving ischemic stroke risk: cholesterol transport, particle burden, vascular inflammation, and immune tone. Superpower measures LDL and HDL (cholesterol carriers), ApoB (atherogenic particle count), Lp(a) (genetically set pro-atherothrombotic lipoprotein), hs-CRP (systemic/vascular inflammation), and white cell ratios NLR and MLR (innate–adaptive immune balance). Together they show how plaque forms, inflames, and may rupture or thrombose.

It quantifies upstream drivers of stroke before events happen. LDL, ApoB, and Lp(a) reflect atherogenic load; hs-CRP reflects arterial inflammation; NLR and MLR reflect immune activation. These markers add precision to traditional risk factors (blood pressure, diabetes, smoking, atrial fibrillation) and help track risk over time. It’s physiology first, identifying mechanisms you can monitor and manage with your clinician.

Yes. With Superpower, our team member can organize a professional blood draw in your home. Same laboratory standards, just more convenient and consistent timing so results are comparable over time.

Start with a baseline. If results are stable and risk is low, yearly is reasonable. If levels are elevated or you’re changing therapies, recheck in about 3–6 months, then space out. Avoid interpreting hs-CRP, NLR, or MLR during or within two weeks of an acute illness, as results can be transiently distorted.

Genetics strongly influences Lp(a). LDL, HDL, and ApoB shift with metabolic state, medications, alcohol, and recent diet. hs-CRP, NLR, and MLR rise with infections, injuries, stress, poor sleep, and smoking; corticosteroids and other drugs can alter white cell ratios. Vigorous exercise, dehydration, and recent illness can transiently change several markers. Fasting status modestly affects lipids.

Fasting is optional; an 8–12 hour fast can improve lipid consistency. Be well hydrated and avoid strenuous exercise for 24 hours. Do not test hs-CRP, NLR, or MLR during an active infection; wait about two weeks after recovery. Take prescribed medications as usual unless your clinician advises otherwise. A morning draw improves repeatability.

References

  1. Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337-345. https://doi.org/10.1161/CIRCOUTCOMES.110.959247
  2. Nave, A. H., Lange, K. S., Leonards, C. O., Siegerink, B., Doehner, W., Landmesser, U., Steinhagen-Thiessen, E., Endres, M., & Ebinger, M. (2015). Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis. Atherosclerosis, 242(2), 496-503. https://doi.org/10.1016/j.atherosclerosis.2015.08.021
  3. Zhou, Y., Han, W., Gong, D., Man, C., & Fan, Y. (2016). Hs-CRP in stroke: A meta-analysis. Clinica Chimica Acta, 453, 21-27. https://doi.org/10.1016/j.cca.2015.11.027
  4. Paudel, S. S., Thapa, B., & Luitel, R. (2021). Neutrophil lymphocyte ratio as a prognostic marker in acute ischemic stroke: A systematic review and meta-analysis. Journal of Nepal Health Research Council, 18(4), 573-579. https://doi.org/10.33314/jnhrc.v18i4.3143
  5. Shin, J., Chung, J. W., Jang, H. S., Lee, J., Hong, K. S., Bang, O. Y., Kim, G. M., & Seo, W. K. (2021). Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. European Journal of Preventive Cardiology, 28(8), 905-916. https://doi.org/10.1177/2047487319830503

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey